UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Nov

    11

    Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)

    Read More Share:linkedin| twitter| email

    Nov

    10

    UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023

    Read More Share:linkedin| twitter| email

    Nov

    09

    Advancing Rheumatic Disease Treatment

    Read More Share:linkedin| twitter| email

    Nov

    06

    Partnering with Caregivers to Advance the Ecosystem of Care for Rare Epilepsies

    Read More Share:linkedin| twitter| email

    Nov

    02

    Supporting Sustainable Communities and Inspiring Science

    Read More Share:linkedin| twitter| email

    Nov

    01

    UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

    Read More Share:linkedin| twitter| email

    Oct

    31

    NAYZILAM® (midazolam) Results Published in Epilepsy & Behavior Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

    Read More Share:linkedin| twitter| email

    Oct

    18

    BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

    Read More Share:linkedin| twitter| email

    Oct

    18

    Evolving Expectations for Dermatological Conditions

    Read More Share:linkedin| twitter| email

    Oct

    17

    UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis

    Read More Share:linkedin| twitter| email

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)